Edwards Lifesciences Corporation [NYSE: EW] traded at a high on 10/14/20, posting a 1.47 gain after which it closed the day’ session at $85.17. The company report on October 7, 2020 that Edwards Lifesciences To Host Earnings Conference Call On October 21, 2020.
Edwards Lifesciences (NYSE: EW), plans to announce its operating results for the quarter ended September 30, 2020 after the market closes on Wednesday, October 21, 2020, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. For 72 hours following the call, an audio replay can be accessed by dialing (877) 660-6853 or (201) 612-7415 and using conference number 13710472. The call will also be available via live or archived webcast on the “Investor Relations” section of the Edwards web site at ir.edwards.com.
The results of the trading session contributed to over 1801790 shares changing hands. Over the past one week, the price volatility of Edwards Lifesciences Corporation stands at 2.43% while the volatility over the past one month is 2.78%.
The market cap for EW stock reached $51.53 billion, with 620.30 million shares outstanding and 617.53 million shares in the current float. Compared to the average trading volume of 2.54M shares, EW reached a trading volume of 1801790 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Edwards Lifesciences Corporation [EW]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EW shares is $86.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EW stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wolfe Research have made an estimate for Edwards Lifesciences Corporation shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on September 11, 2020. While these analysts kept the previous recommendation, Wells Fargo dropped their target price from $250 to $230. The new note on the price target was released on April 28, 2020, representing the official price target for Edwards Lifesciences Corporation stock. Previously, the target price had yet another raise to $270, while SVB Leerink analysts kept a Outperform rating on EW stock.
The Average True Range (ATR) for Edwards Lifesciences Corporation is set at 2.29, with the Price to Sales ratio for EW stock in the period of the last 12 months amounting to 11.92. The Price to Book ratio for the last quarter was 13.76, with the Price to Cash per share for the same quarter was set at 1.92. Price to Free Cash Flow for EW in the course of the last twelve months was 55.01 with Quick ratio for the last quarter at 2.20.
How has EW stock performed recently?
Edwards Lifesciences Corporation [EW] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.50. With this latest performance, EW shares gained by 2.24% in over the last four-week period, additionally plugging by 17.47% over the last 6 months – not to mention a rise of 11.76% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EW stock in for the last two-week period is set at 62.52, with the RSI for the last a single of trading hit 66.35, and the three-weeks RSI is set at 59.29 for Edwards Lifesciences Corporation [EW]. The present Moving Average for the last 50 days of trading for this stock 80.84, while it was recorded at 83.94 for the last single week of trading, and 74.19 for the last 200 days.
Edwards Lifesciences Corporation [EW]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Edwards Lifesciences Corporation [EW] shares currently have an operating margin of +27.55 and a Gross Margin at +73.43. Edwards Lifesciences Corporation’s Net Margin is presently recorded at +24.08.
Return on Total Capital for EW is now 27.98, given the latest momentum, and Return on Invested Capital for the company is 24.53. Return on Equity for this stock inclined to 28.73, with Return on Assets sitting at 17.73. When it comes to the capital structure of this company, Edwards Lifesciences Corporation [EW] has a Total Debt to Total Equity ratio set at 16.36. Additionally, EW Total Debt to Total Capital is recorded at 14.06, with Total Debt to Total Assets ending up at 10.46. Long-Term Debt to Equity for the company is recorded at 15.75, with the Long-Term Debt to Total Capital now at 13.53.
Reflecting on the efficiency of the workforce at the company, Edwards Lifesciences Corporation [EW] managed to generate an average of $75,317 per employee. Receivables Turnover for the company is 7.65 with a Total Asset Turnover recorded at a value of 0.74.Edwards Lifesciences Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 3.10.
Earnings analysis for Edwards Lifesciences Corporation [EW]
With the latest financial reports released by the company, Edwards Lifesciences Corporation posted 0.47/share EPS, while the average EPS was predicted by analysts to be reported at 0.41/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 14.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EW. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Edwards Lifesciences Corporation go to 12.17%.
Insider trade positions for Edwards Lifesciences Corporation [EW]
There are presently around $42,935 million, or 85.30% of EW stock, in the hands of institutional investors. The top three institutional holders of EW stocks are: BLACKROCK INC. with ownership of 59,443,975, which is approximately 6.189% of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 49,428,510 shares of the stock with an approximate value of $4.15 billion in EW stocks shares; and STATE STREET CORP, currently with $2.29 billion in EW stock with ownership of nearly 0.931% of the company’s market capitalization.
Positions in Edwards Lifesciences Corporation stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 486 institutional holders increased their position in Edwards Lifesciences Corporation [NYSE:EW] by around 31,209,210 shares. Additionally, 471 investors decreased positions by around 34,077,109 shares, while 181 investors held positions by with 446,212,853 shares. The mentioned changes placed institutional holdings at 511,499,172 shares, according to the latest SEC report filing. EW stock had 121 new institutional investments in for a total of 6,433,905 shares, while 97 institutional investors sold positions of 5,032,593 shares during the same period.